Generic Name and Formulations:
Auranofin 3mg; caps.
Prometheus Labs, Inc.
Indications for RIDAURA:
Active rheumatoid arthritis unresponsive to NSAIDs.
Initially 6mg daily in 1–2 divided doses. If response inadequate after 6 months, may increase to 3mg 3 times daily. If still ineffective after 3 months, discontinue.
History of gold-induced disorders.
Gold toxicity. Physicians should be experienced in chrysotherapy.
Be fully familiar with chrysotherapy and this product's toxicity and benefits before use. Impaired renal or hepatic function. Inflammatory bowel disease. Rash. History of bone marrow depression. Monitor CBC with differential, platelet count, urinalysis, renal, liver function and for GI bleeding. Discontinue immediately if thrombocytopenia, proteinuria, or hematuria occurs. Pregnancy (Cat.C), nursing mothers: not recommended.
DMARD (gold salt).
Bone marrow depression, proteinuria, hematuria, diarrhea, GI upset, ulcerative colitis, rash, pruritus, exfoliative dermatitis, stomatitis, conjunctivitis, proteinuria, nephrotic syndrome, cholestatic jaundice, gold bronchitis, pneumonitis, peripheral neuropathy.
Neurology Advisor Articles
- Erenumab Superior to Placebo for Reducing Migraine Disability, Improving HRQoL
- Managing Status Epilepticus in Palliative Care: Accounting for Patient and Family Experience
- Congress Passes Bill to Fight Opioid Crisis
- Physical Activity Decreases Vascular Comorbidities in Multiple Sclerosis
- Review of Factors Impacting Sport-Related Concussion Headaches
- Anodal tDCS Offers Possible Benefit for Improving Item Recall in Post-Stroke Aphasia
- Hospitalization Tied to Brain Abnormalities in Older Adults
- Spending Often Persists in High-Cost Medicare-Medicaid Eligible
- Skills-Based Intervention Did Not Cut Systolic BP After Stroke, TIA
- High Frequency of Headaches Following Dialysis Associated With BUN and Blood Pressure